High COX-2 immunoreactivity in tumor spheroids and subcutaneous tumor allografts derived from mouse pheochromocytoma (MPC) cells demonstrates that available PPGL models are suitable for preclinical in vitro and in vivo testing of COX-2-targeting treatments. The gene discussed is PTGS2; the disease is hereditary pheochromocytoma-paraganglioma.